Evaxion announces strategy and business update and third quarter 2026 financial results
Globe Newswire•19/11/2026•07:00 ET
1
Key Highlights
- ➤Cash runway extended toward end-2027 after $2.2 million gross ATM proceeds
- ➤EVX-04 phase 1 trial application remains on track before year-end 2026
- ➤EVX-01 showed 89% vaccine target precision and sustained three-year responses
- ➤Q3 net loss $3.5 million versus $4.6 million profit year-ago
- ➤Evaxion refocuses strategy on immuno-oncology assets and cancer vaccine development
Expert Statements
Helen Tayton-Martin, CEO of Evaxion
“We are refocusing our strategy on the unique capabilities of AI-Immunology™ in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology™ platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology”
COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and business update and announces third quarter 2026 financial results.
Strategy update Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology™ in novel cancer target discovery and cancer vaccine development.
Get started
Create a free account to read the full story.
